FindTrial
Sign In

Clinical study on open angle variety of glaucoma with oral and local medication

Clinical study on Primary Open angle Glaucoma with tarpana and oral medication - POAG (Primary Open angle Glaucoma)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/03/006696
Enrollment
100
Registered
2016-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients of POAG aged between 30-70 years having Intraocular Pressure 21 mm Hg ( Normal Tensive Glaucoma) and 21 mm Hg with Visual acuity 6/60 and clear media

Interventions

Intervention1: Sigrupallava Arka Tarpana: Patients in trial group will receive 6 sittings of Tarpana with Sigrupallava Arka for 7 days with 1 week interval in between. Control Intervention1: Anubhoota

Sponsors

IPGT RA GAU
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Having POAG with Intraoccular Pressure more than 21mmHg and Normal Tension Glaucoma with Intraoccular Pressure less than 21mmHg with visual acuity more than 6/60.

Exclusion criteria

Exclusion criteria: All types of Primary Angle closure Glaucoma, secondary and developmental Glaucoma including Exfoliative Glaucoma, Pigmentary Glaucoma, Trauma induced glaucoma, inflammatory Glaucoma and POAG with advanced stage of Optic Atrophy.

Design outcomes

Primary

MeasureTime frame
To evaluate the role of Ayurvedic line of management in lowering Intraoccular Pressure and neuroprotection in POAGTimepoint: To evaluate the role of Ayurvedic line of management in lowering Intraoccular Pressure and neuroprotection in POAG—

Secondary

MeasureTime frame
To propound the concept of Chakshushya and Rasayana therapy in the management of POAGTimepoint: Till November 2017—

Countries

India

Contacts

Public ContactDr Archana V K

IPGT and RA GAU

bhatrajma2008@gmail.com9428400759

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026